← Open Payments lookup

NPI 1346766169: Open Payments

NPI 1346766169. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,179 in 64 payments from 19 companies in 2025. Trend: 2023 $1,455 · 2024 $1,527 · 2025 $1,179

Food & beverage: $1,179
CompanyPaymentsAmount
GlaxoSmithKline, LLC.10$190
Novo Nordisk Inc12$185
PFIZER INC.8$133
AstraZeneca Pharmaceuticals LP5$91
Salix Pharmaceuticals, a division of Bausch Health US, LLC4$78
Lilly USA, LLC3$55
Otsuka America Pharmaceutical, Inc.3$53
Sumitomo Pharma America, Inc.3$50
Lundbeck LLC2$48
Xeris Pharmaceuticals, Inc.2$42

Products named: TRELEGY ELLIPTA, NURTEC ODT, REXULTI, Rybelsus, XIFAXAN, MOUNJARO, Ozempic, GEMTESA.